Dr. Raje on the Design of the ENDURANCE Trial in Newly Diagnosed Multiple Myeloma

Video

Noopur S. Raje, MD, discusses the ​design of the randomized phase 3 E​NDURANCE trial in ​newly diagnosed multiple myeloma.

Noopur S. Raje, MD, professor of medicine at Harvard Medical School and director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the ​design of the randomized phase 3 E​NDURANCE (E1A11) trial in ​newly diagnosed multiple myeloma.

At the 2020 ASCO Virtual Scientific Program, ​findings from the study showed that carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) did not significantly improve progression-free survival compared with bortezomib (Velcade), lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma who were not intended for up-front autologous stem cell transplant. 

​The trial randomized ​patients to receive KRd (n = 545) ​versus VRd (n = 542), says Raje. Notably, these are 2 of the most commonly used induction regimens in this space, Raje concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,